Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Brainsway ( (BWAY) ) has provided an update.
On March 19, 2026, BrainsWay announced it had completed a $1 million milestone‑based investment in Axis Integrated Mental Health, a management services organization supporting several mental health clinics in Colorado. The payment was triggered by Axis achieving a predefined revenue performance target agreed under an August 2025 strategic equity financing deal, following BrainsWay’s initial $2.3 million equity investment.
Under the agreement, BrainsWay holds a minority stake in Axis through a preferred, annually compounding security with a redemption mechanism for the shares. The move advances BrainsWay’s strategy of partnering with leading U.S. mental health providers to expand access to advanced treatments such as Deep TMS, potentially strengthening its clinic network presence and reinforcing its positioning in the competitive neuromodulation and mental health services market.
The most recent analyst rating on (BWAY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Brainsway stock, see the BWAY Stock Forecast page.
Spark’s Take on BWAY Stock
According to Spark, TipRanks’ AI Analyst, BWAY is a Outperform.
The score is driven primarily by improved financial performance (profitability inflection, high gross margins, strong cash generation, and low leverage) and supportive technical strength (price above key moving averages with positive momentum). Earnings call tone and raised guidance add confidence, while valuation (P/E ~23.6 and no dividend yield provided) is the main moderating factor.
To see Spark’s full report on BWAY stock, click here.
More about Brainsway
BrainsWay Ltd. is a medical technology company specializing in advanced, noninvasive neurostimulation treatments for mental health disorders using its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform. The company, founded in 2003 and operating in the U.S. and Israel, focuses on FDA‑cleared indications for major depressive disorder, obsessive‑compulsive disorder, and smoking addiction, and is pursuing additional psychiatric and neurological uses.
Average Trading Volume: 210,810
Technical Sentiment Signal: Buy
Current Market Cap: $541.6M
For a thorough assessment of BWAY stock, go to TipRanks’ Stock Analysis page.